Rhythm Pharmaceuticals Inc. Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth

Reuters

Sep 10, 2025

<a href="https://laohu8.com/S/RYTM">Rhythm Pharmaceuticals Inc.</a> Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth

Rhythm Pharmaceuticals Inc. provided an update on its long-term growth strategy, highlighting continued growth in global IMCIVREE® sales with $48.5 million in net revenues for Q2 2025. The company is progressing with U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity (HO) expected to be completed in Q3 2025. Additionally, strong results were reported from a Phase 2 trial of oral bivamelagon in acquired HO. Rhythm Pharmaceuticals is well-capitalized, having raised approximately $189.2 million from an upsized public offering of common stock. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566364820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566364820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566364820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 04:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566364820","market":"nz","top_or_hot":-1,"title":"Rhythm Pharmaceuticals Inc. Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RYTM\">Rhythm Pharmaceuticals Inc.</a> Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rhythm Pharmaceuticals Inc. provided an update on its long-term growth strategy, highlighting continued growth in global IMCIVREE® sales with $48.5 million in net revenues for <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. The company is progressing with U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity (HO) expected to be completed in Q3 2025. Additionally, strong results were reported from a Phase 2 trial of oral bivamelagon in acquired HO. Rhythm Pharmaceuticals is well-capitalized, having raised approximately $189.2 million from an upsized public offering of common stock. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals Inc. Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals Inc. Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 04:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RYTM\">Rhythm Pharmaceuticals Inc.</a> Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rhythm Pharmaceuticals Inc. provided an update on its long-term growth strategy, highlighting continued growth in global IMCIVREE® sales with $48.5 million in net revenues for <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. The company is progressing with U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity (HO) expected to be completed in Q3 2025. Additionally, strong results were reported from a Phase 2 trial of oral bivamelagon in acquired HO. Rhythm Pharmaceuticals is well-capitalized, having raised approximately $189.2 million from an upsized public offering of common stock. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL30jYRM:1","article_id":"2566364820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566364820","pubTimestamp":1757448876,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rhythm Pharmaceuticals Inc. provided an update on its long-term growth strategy, highlighting continued growth in global IMCIVREE sales with $48.5 million in net revenues for Q2 2025. The company is progressing with U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity  expected to be completed in Q3 2025. Additionally, strong results were reported from a Phase 2 trial of oral bivamelagon in acquired HO. Rhythm Pharmaceuticals is well-capitalized, having raised approximately $189.2 million from an upsized public offering of common stock. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content us","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"Rhythm Pharmaceuticals Inc.推出关于先进MC4R激动剂和IMCIVREE的演示®销售增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":0.9},"content_text":"Rhythm Pharmaceuticals Inc. Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth\n    \n\n        Rhythm Pharmaceuticals Inc. provided an update on its long-term growth strategy, highlighting continued growth in global IMCIVREE® sales with $48.5 million in net revenues for Q2 2025. The company is progressing with U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity (HO) expected to be completed in Q3 2025. Additionally, strong results were reported from a Phase 2 trial of oral bivamelagon in acquired HO. Rhythm Pharmaceuticals is well-capitalized, having raised approximately $189.2 million from an upsized public offering of common stock. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}